<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> cells often lose contact inhibition to undergo anchorage-independent proliferation and become resistant to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by inactivating the Hippo signaling pathway, resulting in activation of the transcriptional co-activator yes-associated protein (YAP) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the oncogenic mechanisms of YAP are unclear </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using cross-species analysis of expression data, the Notch ligand Jagged-1 (Jag-1) was identified as downstream target of YAP in hepatocytes and <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>) cells </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed the functions of YAP in <z:mp ids='MP_0003331'>HCC</z:mp> cells via overexpression and <z:chebi fb="40" ids="33697">RNA</z:chebi> silencing experiments </plain></SENT>
<SENT sid="4" pm="."><plain>We used transgenic mice that overexpressed a constitutively activated form of YAP (YAP(S127A)), and measured protein levels in <z:mp ids='MP_0003331'>HCC</z:mp> and colorectal and <z:mp ids='MP_0009153'>pancreatic tumor</z:mp> samples from patients </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Human <z:mp ids='MP_0003331'>HCC</z:mp> cell lines and mouse hepatocytes that overexpress YAP(S127A) upregulated Jag-1, leading to activation of the Notch pathway and increased proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>Induction of Jag-1, activation of Notch, and cell proliferation required binding of YAP to its transcriptional partner TEAD4; TEAD4 binding required Mst1/2, but not WNT-Î²-catenin signaling </plain></SENT>
<SENT sid="7" pm="."><plain>Levels of YAP correlated with Jag-1 expression and Notch signaling in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples and shorter survival times of patients with <z:mp ids='MP_0003331'>HCC</z:mp> or <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The transcriptional regulator YAP upregulates Jag-1 to activate Notch signaling in <z:mp ids='MP_0003331'>HCC</z:mp> cells and mouse hepatocytes </plain></SENT>
<SENT sid="9" pm="."><plain>YAP-dependent activity of Jag-1 and Notch correlate in human <z:mp ids='MP_0003331'>HCC</z:mp> and <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> samples with patient survival times, suggesting the use of YAP and Notch inhibitors as therapeutics for <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> </plain></SENT>
</text></document>